Li Yue, Wu Fang-Tian, Wang Li, Liang Jin-Hua, Zhu Hua-Yuan, Wu Jia-Zhu, Wu Wei, Xia Yi, Fan Lei, Liu Hu, Zhang Sheng, Zhang Zhi-Hong, Li Jian-Yong, Xu Wei
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University Nanjing, China.
Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing, China.
Int J Clin Exp Pathol. 2018 Mar 1;11(3):1520-1528. eCollection 2018.
MALT represents the most common subtype in ocular adnexa lymphoma. Little data, however, has been reported in China. We consecutively analyzed 32 patients from April 2008 to January 2016. Median age at diagnosis was 57 (32-90) years. Most patients presented with stage IE (30/32, 87.5%) and the remaining 2 staged IVE. Treatment and followup data were available for 29 patients. Other than resection and biopsy for diagnosis, most of them (20/29, 68.9%) received radiotherapy. The rest underwent chemotherapy (1, 3.5%), both radiotherapy and chemotherapy (2, 6.9%), or 'watch and wait' (6, 20.7%). With a median followup of 28 (6-94) months, all of the patients are alive. Two cases progressed at 24 months and 30 months. Comparing the PFS for four treatment arms, no significant difference can be observed (=0.147). Our data demonstrated the chronic clinical course and excellent prognosis of OAML. For localized cases, surgery combined with radiotherapy is recommended.
黏膜相关淋巴组织淋巴瘤是眼附属器淋巴瘤最常见的亚型。然而，中国报道的数据较少。我们对2008年4月至2016年1月期间的32例患者进行了连续分析。诊断时的中位年龄为57（32 - 90）岁。大多数患者表现为IE期（30/32，87.5%），其余2例为IVE期。29例患者有治疗和随访数据。除了用于诊断的切除和活检外，大多数患者（20/29，68.9%）接受了放疗。其余患者接受化疗（1例，3.5%）、放疗和化疗联合治疗（2例，6.9%）或“观察等待”（6例，20.7%）。中位随访28（6 - 94）个月，所有患者均存活。2例分别在24个月和30个月时病情进展。比较四个治疗组的无进展生存期，未观察到显著差异（P = 0.147）。我们的数据表明眼附属器黏膜相关淋巴组织淋巴瘤临床病程呈慢性且预后良好。对于局限性病例，建议手术联合放疗。
